Sarepta Therapeutics, Inc.: Form 10-K for the period ended Dec 31, 2019
Filed with the SEC on Feb 26, 2020 and accepted by EDGAR at Feb 26, 2020, 16:04 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-10-01 to 2019-12-31 | $100.1m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 12 months2019-01-01 to 2019-12-31 | $380.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months2019-10-01 to 2019-12-31 | $223.1m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2019-10-01 to 2019-12-31 | $81.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 12 months2019-01-01 to 2019-12-31 | $284.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2019-10-01 to 2019-12-31 | −$230.2m | us-gaap:OperatingIncomeLoss |
| Operating income | 12 months2019-01-01 to 2019-12-31 | −$705.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2019-01-01 to 2019-12-31 | $30.7m | us-gaap:InterestExpense |
| Income tax | 3 months2019-10-01 to 2019-12-31 | $711.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 12 months2019-01-01 to 2019-12-31 | $1.2m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2019-10-01 to 2019-12-31 | −$235.7m | us-gaap:NetIncomeLoss |
| Net income | 12 months2019-01-01 to 2019-12-31 | −$715.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2019-10-01 to 2019-12-31 | −$3.16 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 12 months2019-01-01 to 2019-12-31 | −$9.71 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted shares (weighted) | 12 months2019-01-01 to 2019-12-31 | 73,615,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2019-01-01 to 2019-12-31 | −$456.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2019-01-01 to 2019-12-31 | $59.6m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2019-12-31 | $835.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-12-31 | $1.47bn | us-gaap:AssetsCurrent |
| Total assets | At period end2019-12-31 | $1.82bn | us-gaap:Assets |
| Current liabilities | At period end2019-12-31 | $264.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-12-31 | $1.00bn | us-gaap:Liabilities |
| Shareholders' equity | At period end2019-12-31 | $818.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001564590-20-006769. Last ingested by Listed: Nov 14, 2026, 19:58 ET. Listed shows no prices and gives no investment advice.